Schering-Plough Corporation: Q1 1997 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1997, for Schering-Plough Corporation, a global pharmaceutical and healthcare products company. The report includes unaudited consolidated financial statements and management discussion. Notably, the Board of Directors authorized a 2-for-1 stock split on April 22, 1997, with distribution scheduled for June 3, 1997; financial figures presented are pre-split.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Sales (Revenue) | $1,568.1 million | $1,382.7 million |
| Net Income | $375.3 million | $326.6 million |
| Earnings Per Share (EPS) | $1.03 | $0.89 |
| Income Before Taxes Margin | 31.7% | 31.3% |
| Cost of Sales Margin | 18.4% | 19.0% |
| Operating Cash Flow | $189.0 million | $282.9 million |
| Cash and Equivalents (Ending) | $757.1 million | $356.8 million |
| Total Debt (Short-term + Long-term) | $1,081.5 million | $901.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 13% ($185.4 million) year-over-year. Excluding foreign currency fluctuations, organic growth was 16%.
- Profitability: Net income rose 15% to $375.3 million. EPS increased 16% to $1.03. Cost of sales as a percentage of sales improved to 18.4% due to a favorable mix of higher-margin pharmaceutical products.
- Product Performance:
- CLARITIN: Worldwide sales reached $353 million (up from $237 million in 1996), driving significant growth in allergy/respiratory segments.
- PROVENTIL: Sales declined 44% due to generic competition, though the launch of PROVENTIL HFA helped mitigate future losses.
- Animal Health: Sales rose 33% (excluding FX), led by the U.S. launch of NUFLOR.
- Expenses: Selling, general, and administrative (SG&A) expenses rose to 37.8% of sales (from 36.4%) due to increased promotional spending for CLARITIN. R&D spending increased 10% to $179.2 million.
- Liquidity: Cash and cash equivalents increased by $222.0 million, driven by operating cash flow and a net increase in short-term borrowings of $205.8 million.
Guidance, Outlook, and Risks
- Dividends and Buybacks: The quarterly dividend was increased 15% to $0.38 per share. The $500 million share repurchase program authorized in September 1996 was approximately 74% complete as of March 31, 1997.
- Legal Contingencies: The company is a defendant in over 160 antitrust actions regarding price discrimination. A federal class action was settled for $22.1 million payable over three years. New litigation was filed in April 1997 alleging failure to implement settlement commitments; the company believes these claims are without merit.
- Market Risks: Management highlights risks from government-mandated cost containment, generic competition (specifically for PROVENTIL), and uncertainties in patent disputes and regulatory approvals.
- Accounting Changes: The company noted the upcoming adoption of SFAS No. 128 regarding Earnings Per Share reporting in Q4 1997.
Investor Verification Checklist
- Stock Split Impact: Verify post-split share counts and adjusted EPS ($0.51 pro forma) for accurate valuation comparisons.
- Generic Competition: Monitor the trajectory of PROVENTIL sales decline and the market uptake of the new PROVENTIL HFA inhaler.
- Antitrust Litigation: Track the status of the new April 1997 class action regarding settlement implementation and potential injunctions.
- Cash Flow Volatility: Note the significant decrease in operating cash flow ($189.0M vs $282.9M) despite higher net income, driven by increased accounts receivable and prepaid expenses.
- Debt Structure: Review the increase in short-term borrowings ($205.8M net increase) and its impact on liquidity ratios.